|
LOBBYING REPORT |
Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page
2. Address
| Address1 | 1050 K STREET, NW, #800 |
Address2 |
|
| City | WASHINGTON |
State | DC |
Zip Code | 20001 |
Country | USA |
3. Principal place of business (if different than line 2)
| City |
|
State |
|
Zip Code |
|
Country |
|
|
5. Senate ID# 16293-12
|
||||||||
|
6. House ID# 314610000
|
||||||||
| TYPE OF REPORT | 8. Year | 2019 |
Q1 (1/1 - 3/31) | Q2 (4/1 - 6/30) | Q3 (7/1 - 9/30) | Q4 (10/1 - 12/31) |
9. Check if this filing amends a previously filed version of this report
| 10. Check if this is a Termination Report | Termination Date |
|
11. No Lobbying Issue Activity |
| INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13 | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| 12. Lobbying | 13. Organizations | ||||||||
| INCOME relating to lobbying activities for this reporting period was: | EXPENSE relating to lobbying activities for this reporting period were: | ||||||||
|
|
||||||||
|
|
||||||||
| Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options. | ||||||||
|
Method A.
Reporting amounts using LDA definitions only
Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code |
|||||||||
| Signature | Digitally Signed By: William J. Schuyler |
Date | 10/21/2019 4:52:36 PM |
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code BUD
16. Specific lobbying issues
___ H.R. 21: Consolidated Appropriations Act, 2019 - FDA provisions related to prescription drugs
___ H.R. 265: Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2019 - FDA provisions related to prescription drugs
House
___ H.R. 648: Consolidated Appropriations Act, 2019 - FDA provisions related to prescription drugs
___ H.R. 2500: National Defense Authorization Act for Fiscal Year 2020 - DoD provisions related to prescription drugs
___ H.R. 2740: Labor, Health and Human Services, Education, Defense, State, Foreign Operations, and Energy and Water Development Appropriations Act, 2020 - HHS provisions related to prescription drugs
___ H.R. 2745: Military Construction, Veterans Affairs, and Related Agencies Appropriations Act, 2020 - VA Provisions related to prescription drugs
___ H.R. 2968: Department of Defense Appropriations Act, 2020 - DoD provisions related to prescription drugs
___ H.R. 3055: Making appropriations for the Departments of Commerce and Justice, Science, and Related Agencies for the fiscal year ending September 30, 2020, and for other purposes - FDA provisions related to prescription drugs
___ H.R. 3164: Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2020 - FDA provisions related to prescription drugs
_H.R. 3877 Bipartisan Budget Act of 2019
___ H.R. 4378: Continuing Appropriations Act, 2020, and Health Extenders Act of 2019 - Provisions related to Medicare funding
___ H. Res. 28: Providing for consideration of the bill (H.R. 264) making appropriations for financial services and general government for the fiscal year ending September 30, 2019, and for other purposes; providing for consideration of the bill (H.R. 265) making appropriations for Agriculture, Rural Development, Food and Drug Administration, and Related Agencies programs for the fiscal year ending September 30, 2019, and for other purposes; providing for consideration of the bill (H.R. 266) making appropriations for the Department of the Interior, environment, and related agencies for the fiscal year ending September 30, 2019, and for other purposes; providing for consideration of the bill (H.R. 267) making appropriations for the Department of Transportation, and Housing and Urban Development, and related agencies for the fiscal year ending September 30, 2019, and for other purposes; and waiving a requirement of clause 6(a) of rule XIII with respect to consideration of certain resolutions reported from the Committee on Rules.
___ H. Res. 293: Providing for budget enforcement for fiscal year 2020
___ H. Res. 436: Providing for further consideration of the bill (H.R. 2740) making appropriations for the Departments of Labor, Health and Human Services, and Education, and related agencies for the fiscal year ending September 30, 2020, and for other purposes
___ H. Res. 4455: Providing for consideration of the bill (H.R. 3055) making appropriations for the Departments of Commerce and Justice, Science, and Related Agencies for the fiscal year ending September 30, 2020, and for other purposes; relating to consideration of the bill (H.R. 2740) making appropriations for the Departments of Labor, Health and Human Services, and Education, and related agencies for the fiscal year ending September 30, 2020, and for other purposes; and providing for proceedings during the period from June 28, 2019, through July 8, 2019
___ S. 1215: National Defense Authorization Act for Fiscal Year 2020 - DoD provisions related to prescription drugs
___ S. 1790: National Defense Authorization Act for Fiscal Year 2020 - DoD provisions related to prescription drugs
___ S. 2474: Department of Defense Appropriations Act, 2020 - DoD provisions related to prescription drugs
___ S. 2522: Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2020 - FDA provisions related to prescription drugs
___ S. ___: Making appropriations for the Departments of Labor, Health and Human Services, and Education, and related agencies for the fiscal year ending September 30, 2020, and for other purposes
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Office of Management & Budget (OMB)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
William |
Schuyler |
|
|
|
Kimberly |
Williams |
|
|
|
Jonathan |
Causey |
|
|
|
Michael |
Calvo |
|
|
|
Philip |
Thevenet |
|
|
|
Alec |
Hinojosa |
|
|
|
Jennifer |
Dale |
|
SScheduler/Executive Assistant, Rep. Jason Altmire, Jan. 2012 - Sept. 2012;
Director of Operations, Rep. Mike Thompson, Sept. 2012-Nov. 2015
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code CPT
16. Specific lobbying issues
H.R. 465: Prescription Drug Price Relief Act of 2019 - Provisions related to foreign reference pricing, patents and march-in rights
H.R. 938: BLOCKING Act of 2019 - Provisions related to 180 day generic prescription drug exclusivity
H.R. 987: Strengthening Health Care and Lowering Prescription Drug Costs Act - Provisions related to prescription drug patent issues
H.R. 990: Hatch-Waxman Integrity Act of 2019 - Provisions related to PTAB proceedings and other patent system reforms
H.R. 1188: FLAT Prices Act - Provisions related to prescription drug patents, exclusivity periods and pricing
H.R. 1499: Protecting Consumer Access to Generic Drugs Act of 2019 - Provisions related to patent settlements
H.R. 1503: Orange Book Transparency Act - Provisions related to prescription drug and device patent listings
H.R. 1520: Purple Book Continuity Act of 2019 - Provisions related to prescription drug patent listings
___ H.R. 2374: Stop STALLING Act - Provisions related to citizen petitions
___ H.R. 2375: Preserve Access to Affordable Generics and Biosimilars Act - Provisions related to patent settlements
___ H.R. 2387: STOP GAMES Act of 2019 - Provisions related to citizen petitions
___ H.R. 2455: Ensuring Timely Access to Generics Act of 2019 - Provisions related to citizen petitions
___ H.R. 2700: Lowering Prescription Drug Costs and Extending Community Health Centers and Other Public Health Priorities Act - Provisions related to patent settlements, generic exclusivity, Risk Evaluation and Mitigation Strategies (REMS) and limited distribution systems
___ H.R. 3199: Terminating the Extension of Rights Misappropriated Act of 2019 - Provisions related to prescription drug patents
___ H.R. 3666: STRONGER Patents Act of 2019 - Provisions related to prescription drug patents
___ H.R. 4398: Affordable Prescriptions for Patients Through Promoting Competition Act of 2019 - Provisions related to prescription drug patents
___ S. 64: Preserve Access to Affordable Generics and Biosimilars Act - Provisions related to patent settlements
___ S. 102: Prescription Drug Price Relief Act of 2019 - Provisions related to foreign reference pricing, patents and march-in rights
___ S. 344: Hatch-Waxman Integrity Act of 2019 - Provisions related to PTAB proceedings and other patent system reforms
___ S. 366: FLAT Prices Act - Provisions related to prescription drug patents, exclusivity periods and pricing
___ S. 659: Biologic Patent Transparency Act - Provisions related to prescription drug patent disclosures
___ S. 1169: Ensuring Timely Access to Generics Act of 2019 - Provisions related to citizen petitions
___ S. 1209: Reforming Evergreening and Manipulation that Extends Drug Years Act - Provisions related to prescription drug patents
___ S. 1224: Stop STALLING Act - Provisions related to citizen petitions
___ S. 1416: Affordable Prescriptions for Patients Act of 2019 - Provisions related to prescription drug patents
___ S. 1617: Second Look at Drug Patents Act of 2019 - Provisions related to prescription drug patents
___ S. 1636: Ensuring Innovation Act - Provisions related to new chemical exclusivity
___ S. 2082: STRONGER Patents Act of 2019 - Provisions related to prescription drug patents
___ Biopharmaceutical innovation and patent policy issues
___ Patent litigation reform issues and issues related to post-grant proceeding at the PTO
___ Bayh-Dole march-in rights policy issues
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Patent & Trademark Office (PTO)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
William |
Schuyler |
|
|
|
Kimberly |
Williams |
|
|
|
Jonathan |
Causey |
|
|
|
Michael |
Calvo |
|
|
|
Philip |
Thevenet |
|
|
|
Alec |
Hinojosa |
|
|
|
Jennifer |
Dale |
|
SScheduler/Executive Assistant, Rep. Jason Altmire, Jan. 2012 - Sept. 2012;
Director of Operations, Rep. Mike Thompson, Sept. 2012-Nov. 2015
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HCR
16. Specific lobbying issues
H.R. 447: Affordable and Safe Prescription Drug Importation Act - Provisions related to importation
___ H.R. 478: Safe and Affordable Drugs from Canada Act of 2019 - Provisions related to importation
___ H.R. 965: Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2019 - Provisions related to Risk Evaluation and Mitigation Strategies (REMS) and limited distribution systems
___ H.R. 985: FAST Generics Act of 2019 - Provisions related to Risk Evaluation and Mitigation Strategies (REMS) and limited distribution systems
H.R. 1922/S. 1089 _ Restoring Access to Medicine Act
___ H.R. 1093: Stop Price Gouging Act - Provisions related to prescription drug pricing
___ H.R. 1332: Fair Care Act of 2019 - Provisions related to prescription drug pricing, patent issues, Risk Evaluation and Mitigation Strategies (REMS) and limited distribution systems
___ H.R. 1409: Transparency in All Health Care Pricing Act of 2019 - Provisions related to prescription drug pricing transparency
___ H.R. 1506: Fair and Immediate Release of (FAIR) Generic Drugs Act - Provisions related to generic prescription drug approvals
H.R. 1973: Vaccine Access Improvement Act
___ H.R. 2011: Protecting Access to Biosimilars Act of 2019 - Provisions related to biological products
___ H.R. 2038: State-Based, Market-Oriented, Prescription Drug Negotiations Act of 2019 - Provisions related to prescription drug pricing
___ H.R. 2064: To amend title XI of the Social Security Act to require manufacturers of certain drugs, devices, biologicals, and medical supplies to report on product samples provided to certain health care providers, and for other purposes - Provisions related to prescription drug samples
___ H.R. 2069: Stopping the Pharmaceutical Industry from Keeping Drug Expensive (SPIKE) Act of 2019 - Provisions related to increases in the wholesale acquisition costs of prescription drugs
___ H.R. 2087: Drug Price Transparency Act - Provisions related to prescription drug pricing and transparency
___ H.R. 2113: Prescription Drug STAR Act - Provisions related to prescription drug pricing, reporting and product samples
___ H.R. 2115: Public Disclosure of Drug Discounts Act - Provisions related to prescription drug pricing transparency and pharmacy benefit managers
___ H.R. 2296: FAIR Drug Pricing Act of 2019 / More Efficient Tools to Realize Information for Consumers Act - Provisions related to prescription drug pricing and transparency
___ H.R. 2376: Prescription Pricing for the People Act of 2019 - Provisions related to prescription drug pricing transparency and pharmacy benefit managers
___ H.R. 2401: American Cures Act - Provisions related to pharmaceutical research and development
___ H.R. 3223: Pharmacy Benefit Manager Accountability Study Act of 2019 - Provisions related to prescription drug pricing transparency and pharmacy benefit managers
___ H.R. 3327: Drug Price Transparency for Medicare Patients Act of 2019 - Provisions related to direct-to-consumer prescription drug advertising
___ H.R. 3415: Real-Time Beneficiary Drug Cost Bill - Provisions related to drug pricing transparency
___ H.R. 3443: Over-the-Counter Monograph Safety, Innovation, and Reform Act of 2019 - Provisions related to FDA over-the-counter drug approvals
___ H.R. 3947: Competition Prescription Act of 2019 - Provisions related to prescription drug pricing, patents, and other provisions
___ H.R. 4106: Responsibility in Drug Advertising Act of 2019 - Provisions related to direct-to-consumer prescription drug advertising
___ H.R. 4158: CURE High Drug Prices Act - Provisions related to prescription drug pricing and transparency
___ H.R. 4538: To amend title III of the Public Health Service Act to limit the orphan drug exclusion under the drug discount program under section 340B of such title. - Provisions related to 340B prescription drug exclusions
___ S. 61: Safe and Affordable Drugs from Canada Act of 2019 - Provisions related to importation
___ S. 73: End Taxpayer Subsidies for Drug Ads Act - Provisions related to direct-to-consumer prescription drug advertising
___ S. 97: Affordable and Safe Prescription Drug Importation Act - Provisions related to importation
___ S. 340: Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2019 - Provisions related to Risk Evaluation and Mitigation Strategies (REMS) and limited distribution systems
___ S. 378: Stop Price Gouging Act - Provisions related to prescription drug pricing
___ S. 440: PACED Act - Provisions related to use of sovereign immunity in patent disputes
___ S. 474: Stopping the Pharmaceutical Industry from Keeping Drug Expensive (SPIKE) Act of 2019 - Provisions related to increases in the wholesale acquisition costs of prescription drugs
___ S. 637: Combatting Unreasonable Rises and Excessively (CURE) High Drug Prices Act - Provisions related to prescription drug pricing and transparency
___ S. 657: Drug Price Transparency Act - Provisions related to prescription drug pricing transparency and commercial market rebates
___ S. 658: Accelerated Drug Approval for Prescription Therapies Act - Provisions related to FDA drug approvals
___ S. 660: Efficiency and Transparency in Petitions Act - Provisions related to the FDA citizen petition process
___ S. 844: Short on Competition Act - Provisions related to generic prescription drug approvals and importation
___ S. 977: Transparent Drug Pricing Act of 2019 - Provisions related to pharmaceutical drug pricing
___ S. 1140: Protecting Access to Biosimilars Act of 2019 - Provisions related to biological products
___ S. 1227: Prescription Pricing for the People Act of 2019 - Provisions related to prescription drug pricing transparency and pharmacy benefit managers
___ S. 1384: Prescription Drug Rebate Reform Act of 2019 - Provisions related to prescription drug pricing and commercial rebates
___ S. 1391: FAIR Drug Pricing Act of 2019 - Provisions related to prescription drug pricing and transparency
___ S. 1437: Drug-price Transparency in Communications (DTC) Act - Provisions related to direct-to-consumer prescription drug advertising
___ S. 1532: Pharmacy Benefit Manager Accountability Study Act of 2019 - Provisions related to prescription drug pricing transparency and pharmacy benefit managers
___ S. 1664: Prescription Drug Price Reporting Act - Provisions related to prescription drug pricing transparency
S.1872 _ Protecting Seniors through Immunizations Act of 2019
___ S. 2387: We Protect American Investment in Drugs Act - Provisions related to prescription drug pricing
___ Transparency policy issues
___ Drug cost and pricing policy issues
___ Drug importation and counterfeiting policy issues
___ HHS Safe Importation Action Plan
___ Prescription drug take back and secure disposal policy issues
___ Policy issues related to prescription drug abuse and opioids
___ Expanded access policy issues
___ Generic drug approval process policy issues
___ High deductible health plans/HSA policy issues
___ Sharing of truthful and non-misleading information about medicines with healthcare professionals and payors
___ Risk Evaluation and Mitigation Strategy (REMS) policy issues
___ FDA modernization policy issues
___ PDUFA implementation policy issues
___ 340B drug discount program policy issues
___ Bipartisan Budget Act of 2018 (Public Law 115-123) - Part D provisions
___ Patient assistance program policy issues
___ Biosimilar approval and reimbursement policy issues
___ Cancer drug vial size policy issues
___ TRICARE pharmacy pilot program
___ Drug shortages policy issues
___ Request for Information: HHS Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs (RIN 0991-ZA49)
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Health & Human Services - Dept of (HHS), Office of Management & Budget (OMB), Defense - Dept of (DOD)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
William |
Schuyler |
|
|
|
Kimberly |
Williams |
|
|
|
Jonathan |
Causey |
|
|
|
Michael |
Calvo |
|
|
|
Philip |
Thevenet |
|
|
|
Alex |
Hinojosa |
|
|
|
Jennifer |
Dale |
|
Scheduler/Executive Assistant, Rep. Jason Altmire, Jan. 2012 - Sept. 2012;
Director of Operations, Rep. Mike Thompson, Sept. 2012-Nov. 2015
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MMM
16. Specific lobbying issues
___ H.R. 3: Lower Drug Costs Now Act of 2019 - Provisions related to prescription drug pricing, foreign reference pricing, Part D, manufacturer rebates, and other provisions
___ H.R. 107: To amend title XIX of the Social Security Act to sunset the limit on the maximum rebate amount for single source drugs and innovator multiple source drugs - Provisions related to Medicaid drug rebates
___ H.R. 275: Medicare Prescription Drug Price Negotiation Act of 2019 - Provisions related to Part D and drug pricing negotiation
___ H.R. 448: Medicare Drug Price Negotiation Act - Provisions related to Part D and drug pricing negotiation
___ H.R. 937: Right Rebate Act of 2019 - Provisions related to Medicaid drug rebates and drug classification
___ H.R. 1034: Phair Pricing Act of 2019 - Provisions related to Part D and manufacturer rebates
___ H.R. 1035: Prescription Drug Price Transparency Act - Provisions related to drug pricing transparency and pharmacy benefit managers
___ H.R. 1046: Medicare Negotiation and Competitive Licensing Act of 2019 - Provisions related to Part D, drug pricing negotiation and compulsory licensing
___ H.R. 1346: Medicare Buy-In and Health Care Stabilization Act of 2019 - Provisions related to Part D and drug pricing negotiation
___ H.R. 1384: Medicare for All Act of 2019 - Provisions related to Part D, drug pricing negotiation and march-in rights
___ H.R. 1839: Medicaid Services Investment and Accountability Act - Provisions related to Medicaid drug rebates and drug classification
___ H.R. 2000: Medicare-X Choice Act of 2019 - Provisions related to Part D and drug pricing negotiation
___ H.R. 2452: Medicare for America Act of 2019 - Provisions related to Part D and drug pricing negotiation
___ H.R. 2463: Choose Medicare Act - Provisions related to Part D and drug pricing negotiation
___ H.R. 2757: Creating Lower cost Alternative for Your prescription drugs Act - Provisions related to Part D and patient cost-sharing
___ H.R. 3029: Improving Low-Income Access to Prescription Drugs Act of 2019 - Provisions related to Part D prescription drug plans
___ H.R. 3523: End Price Gouging for Medications Act - Provisions related to prescription drug pricing and foreign reference pricing
___ H.R. 3910: Equality in Medicare and Medicaid Treatment Act of 2019 - Provisions related to CMMI models
___ S. 62: Empowering Medicare Seniors to Negotiate Drug Prices Act of 2019 - Provisions related to Part D and drug pricing negotiation
___ S. 99: Medicare Drug Price Negotiation Act - Provisions related to Part D and drug pricing negotiation
___ S. 205: Right Rebate Act of 2019 - Provisions related to Medicaid drug rebates and drug classification
___ S. 377: Medicare Negotiation and Competitive Licensing Act of 2019 - Provisions related to Part D, drug pricing negotiation and compulsory licensing
___ S. 475: Reducing Existing Costs Associated with Pharmaceuticals for Seniors (RxCap) Act of 2019 - Provisions related to Part D and patient cost-sharing
___ S. 470: Medicare at 50 Act - Provisions related to Part D and drug pricing negotiation
___ S. 476: Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act of 2019 - Provisions related to transparency of prescription drug pricing and pharmacy benefit managers
___ S. 640: Phair Pricing Act of 2019 - Provisions related to Part D and manufacturer rebates
___ S. 691: Medicare Extra Rx Higher Eligibility Limits in Part D Act of 2019 - Provisions related to Part D and patient out-of-pocket costs
___ S. 801: Payment Commission Data Act - Provisions related to prescription drug pricing transparency and reporting
___ S. 981: Medicare-X Choice Act of 2019 - Provisions related to Part D and drug pricing negotiation
___ S. 1129: Medicare for All Act of 2019 - Provisions related to Part D and drug pricing negotiation
___ S. 1261: Choose Medicare Act - Provisions related to Part D and drug pricing negotiation
___ S. 1497: Health Care Price Check Act of 2019 - Provisions related to Medicare pricing transparency
___ S. 1785: Fair AMP Act - Provisions related to Medicaid drug rebates
___ S. 1801: Affordable Medications Act - Provisions relate to Part D drug pricing negotiation, importation, IP issues and pricing transparency
___ S. 1895: Lowering Health Care Costs Act - Provisions related to prescription drug pricing, transparency and patent issues
___ S. 1897: A bill to establish a process for updating the labeling of certain drugs with outdated labeling - Provisions related to prescription drug labeling
___ S. 1987: End Price Gouging for Medications Act - Provisions related to prescription drug pricing and foreign reference pricing
___ S. 1999: Improving Low-Income Access to Prescription Drugs Act of 2019 - Provisions related to Part D prescription drug plans
___ S. 2051: Strengthening Average Sales Price Reporting Act - Provisions related to Medicare pricing transparency and rebates
___ S. 2081: Stop Drug Companies from Overcharging Seniors in Medicare Part B Act of 2019 - Provisions related to prescription drug pricing and manufacturer rebates
___ S. 2247: Phair Pricing Act of 2019 - Provisions related to Part D and manufacturer rebates
___ S. 2252: Empowering States to Address Drug Costs Act - Provisions related to prescription drug pricing transparency
___ S. 2543: Prescription Drug Pricing Reduction Act of 2019 - Provisions related to prescription drug pricing, transparency, manufacturer rebates and other provisions
___ Medicare Access and Childrens Health Insurance Program (CHIP) reauthorization policy issues
___ Department of Health and Human Services (HHS) drug policy issues and regulatory policy issues
___ Part D policy issues including non-interference and rebates policy issues
___ Part B reform including MedPAC recommendations and other policy issues and local coverage decisions
___ Drug cost and pricing policy issues
___ Transparency policy issues
___ Alternative payment models policy issues
___ Value-based purchasing arrangements policy issues
___ Anti-Kickback Statute policy issues
___ Center for Medicare and Medicaid Innovation (CMMI) policy issues
___ Medicaid rebates and waiver policy issues
___ Prescription drug abuse policy issues
___ ANPRM; Medicare Program; International Pricing Index Model for Medicare Part B Drugs (CMS-5528-ANPRM)
___ Proposed Rule; Medicare and Medicaid Programs; Regulation To Require Drug Pricing Transparency (CMS-4187-P)
___ Proposed Rule; Contract Year (CY) 2020 Medicare Advantage and Part D Drug Pricing (CMS-4180-P)
___ Request for Information: Medicare and State Health Care Programs: Fraud and Abuse; Request for Information Regarding the Anti-Kickback Statute and Beneficiary Inducements CMP; 83 Fed. Reg. 43607 (Aug. 27, 2018)
___ Removal of Safe Harbor Protection for Rebates to Plans or PBMs Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection (RIN 0936-AA08)
Monograph Reform and HSA/FSAs
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Health & Human Services - Dept of (HHS), Centers For Medicare and Medicaid Services (CMS), Office of Management & Budget (OMB), Defense - Dept of (DOD)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
William |
Schuyler |
|
|
|
Kimberly |
Williams |
|
|
|
Jonathan |
Causey |
|
|
|
Michael |
Calvo |
|
|
|
Philip |
Thevenet |
|
|
|
Alec |
Hinojosa |
|
|
|
Jennifer |
Dale |
|
Scheduler/Executive Assistant, Rep. Jason Altmire, Jan. 2012 - Sept. 2012;
Director of Operations, Rep. Mike Thompson, Sept. 2012-Nov. 2015
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code TRD
16. Specific lobbying issues
___ H.R. 2209: Fixing Global Freeloading Act - Provisions related to trade policy issues and international pharmaceutical drug pricing issues
___ Trade Agreements including NAFTA, USMCA and related policy issues
___ Biopharmaceutical innovation policy issues
___ International intellectual property and market access policy issues
___ Pricing and reimbursement policy issues
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, U.S. Trade Representative (USTR)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
William |
Schuyler |
|
|
|
Kimberly |
Williams |
|
|
|
Shira |
Kilcoyne |
|
|
|
Jonathan |
Causey |
|
|
|
Michael |
Calvo |
|
|
|
Philip |
Thevenet |
|
|
|
Alec |
Hinojosa |
|
|
|
Jennifer |
Dale |
|
Scheduler/Executive Assistant, Rep. Jason Altmire, Jan. 2012 - Sept. 2012;
Director of Operations, Rep. Mike Thompson, Sept. 2012-Nov. 2015
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Information Update Page - Complete ONLY where registration information has changed.
20. Client new address
| Address |
|
||||||
| City |
|
State |
|
Zip Code |
|
Country |
|
21. Client new principal place of business (if different than line 20)
| City |
|
State |
|
Zip Code |
|
Country |
|
22. New General description of client’s business or activities
LOBBYIST UPDATE
23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client
|
|
||||||||
| 1 |
|
3 |
|
||||||
| 2 |
|
4 |
|
ISSUE UPDATE
24. General lobbying issue that no longer pertains
|
|
|
|
|
|
|
|
|
AFFILIATED ORGANIZATIONS
25. Add the following affiliated organization(s)
Internet Address:
| Name | Address |
Principal Place of Business (city and state or country) |
||||||||||||
| ||||||||||||||
|
||||||||||||||
26. Name of each previously reported organization that is no longer affiliated with the registrant or client
| 1 | 2 | 3 |
FOREIGN ENTITIES
27. Add the following foreign entities:
| Name | Address |
Principal place of business (city and state or country) |
Amount of contribution for lobbying activities | Ownership percentage in client | ||||||||||
| ||||||||||||||
|
% | |||||||||||||
28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization
| 1 | 3 | 5 |
| 2 | 4 | 6 |
CONVICTIONS DISCLOSURE
29. Have any of the lobbyists listed on this report been convicted in a Federal or State Court of an offense involving bribery,
extortion, embezzlement, an illegal kickback, tax evasion, fraud, a conflict of interest, making a false statement, perjury, or money laundering?
| Lobbyist Name | Description of Offense(s) |